[MRI can be prescribed in patients with implanted cardiac devices (pacemaker, defibrillator) to optimize radiotherapy planning].

Une IRM peut être prescrite en situation de dispositif cardiaque implantable (pacemaker, défibrillateur), application à la radiothérapie.
Cardiovascular implantable electronic device Contraindication Contre-indication Defibrillator Dispositif cardiaque implantable Défibrillateur Imagerie Imaging Magnetic resonance imaging MRI Pacemaker Procedure Procédure Radiation therapy Radiothérapie Résonance magnétique IRM

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 27 10 2019
revised: 14 12 2019
accepted: 18 12 2019
pubmed: 24 5 2020
medline: 26 6 2020
entrez: 24 5 2020
Statut: ppublish

Résumé

MRI is sometimes critical to optimal radiotherapy planning but may be contraindicated in increasing numbers of patients who carry an implantable cardiac device (ICD, pacemaker or defibrillator). This literature search reviews studies of MRI in DCI patients, morbidity and procedures for the different types of ICD. Several retrospective studies and two recent large prospective studies have shown that the use of an ICD is not an absolute contraindication to MRI, given that specific DCI monitoring is performed under the tridisciplinary supervision of the oncologist, radiologist and cardiologist for MRI≤1.5T. The rate of major complications is less than 5% unless probe replacement is performed. When it can be anticipated, new MRI-compatible ICD can be implanted rather than conventional ICD, but probe replacement is not currently recommended. Data for MRI beyond 1.5T and in case of MRI repeatability in the context of MRI-Linac treatments are lacking. MRI may be performed in ICD patients, as the risk of morbidity is very low; provided that tridisciplinary evaluation is performed.

Identifiants

pubmed: 32444285
pii: S1278-3218(20)30042-1
doi: 10.1016/j.canrad.2019.12.001
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

340-344

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

J Bouter (J)

Département de radiothérapie. centre François-Baclesse, ARCHADE, 3, avenue General-Harris, 14000 Caen, France.

J Lacroix (J)

Département de radiologie, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France.

J Baud (J)

Département d'imagerie médicale, centre hospitalier universitaire, 14000 Caen, France.

J Thariat (J)

Département de radiothérapie. centre François-Baclesse, ARCHADE, 3, avenue General-Harris, 14000 Caen, France; Laboratoire de physique corpusculaire, IN2P3/ENSICAEN, UMR6534, Caen, France; Unicaen, Normandie université. Electronic address: jthariat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH